European Journal of Health Economics

Papers
(The H4-Index of European Journal of Health Economics is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Education and medication use later in life and the role of intelligence68
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication67
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system56
Costing methodologies in European economic evaluation guidelines: commonalities and divergences55
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries55
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis50
Correction to: Geographic distribution of physicians in Portugal39
Characteristics and health care costs in patients with a diagnostic imaging for low back pain in Switzerland38
Psychometric properties and general population reference values for PROMIS Global Health in Hungary37
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland30
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions29
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study28
The hidden cost of sophistication: economic complexity and obesity27
The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study26
Prescription opioids and economic hardship in France25
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial25
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands23
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan23
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study23
Workload and short sickness absences in a cohort of Finnish hospital employees23
Setting incentives right with long-term risk adjustment22
The employment situation of people living with HIV: a closer look at the effects of the 2008 economic crisis22
Production losses due to mortality associated with modifiable health risk factors in Poland22
0.061861991882324